By staff writers

June 12, 2012 -- ITG Isotope Technologies Garching and NTP Radioisotopes, a subsidiary of the South African Nuclear Energy Corporation (NECSA), announced that they will collaborate to guarantee that Brazil and African countries will have a reliable supply of high-quality radioisotopes.

As a first step, they have agreed on a technology transfer for the unique isotope ITG Lu-177 noncarrier added (n.c.a.). Lutetium-177 is used in nuclear medicine for the treatment of neuroendocrine tumors. NTP has in-licensed the production technology and will become the exclusive distribution partner for ITG.

In addition, ITG will expand its global reactor network by cooperating with NECSA's Safari-1 nuclear reactor. The Safari-1 nuclear reactor is one of five reactors in the world that together produce 98% of the world's radionuclides for medical use.

Copyright © 2012

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking